Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer
- 1 February 2020
- journal article
- research article
- Published by Elsevier in Cellular Immunology
- Vol. 348, 104041
Abstract
No abstract availableKeywords
Funding Information
- National Key Research and Development Program of China (2017YFC1200503)
This publication has 37 references indexed in Scilit:
- Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted ImmunotherapyJournal of Immunotherapy, 2019
- A safe and potent anti-CD19 CAR T cell therapyNature Medicine, 2019
- Clinical development of anti‐CD19 chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphomaCancer Science, 2017
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaMolecular Therapy, 2017
- Adoptive cellular therapy: A race to the finish lineScience Translational Medicine, 2015
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen ReceptorJournal of Clinical Oncology, 2015
- Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander EffectMolecular Cancer Therapeutics, 2014
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- Mesothelin targeted cancer immunotherapyEuropean Journal of Cancer, 2008
- MesothelinClinical Cancer Research, 2004